Epo Receptors Are Not Detectable in Primary Human Tumor Tissue Samples

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Elliott, Steve ^a   Swift, Susan ^a   Busse, Leigh ^a   Scully, Sheila ^a   Van, Gwyneth ^a   Rossi, John ^a   Johnson, Carol ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; ERYTHROPOIETIN RECEPTOR ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL LEVEL; COLON CANCER; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FALSE POSITIVE RESULT; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR BINDING; SKIN CANCER; TISSUE LEVEL;

ANIMALS; BIOPSY; CELL LINE, TUMOR; FALSE POSITIVE REACTIONS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOASSAY; MALE; MICE; NEOPLASM PROTEINS; NEOPLASMS; PHOSPHORYLATION; RECEPTORS, ERYTHROPOIETIN; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84879821115     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068083     Document Type: Article

References (78)

1. Krantz SB, (1991) Erythropoietin. Blood 77: 419-434.
2. Elliott S, Sinclair AM, (2012) The effect of erythropoietin on normal and neoplastic cells. Biologics: Targets and Therapy 6: 163-189.
3. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, et al. (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110: 477-488.
4. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ, (2008) The erythropoietin receptor in normal and cancer tissues. Critical Reviews in Oncology-Hematology 67: 39-61.
5. Sinclair AM, Rogers N, Busse L, Archibeque I, Brown W, et al. (2008) Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. British Journal of Cancer 98: 1059-1067.
6. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, et al. (2006) Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 107: 1892-1895.
7. Kirkeby A, van BJ, Nielsen J, Leist M, Helboe L, (2007) Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. Journal of Neuroscience Methods 164: 50-58.
8. Laugsch M, Metzen E, Svensson T, Depping R, Jelkmann W, (2008) Lack of functional erythropoietin receptors of cancer cell lines. International Journal of Cancer 122: 1005-1011.
9. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, et al. (2010) Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18: 423-435.
10. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, et al. (2010) Absence of functional EpoR expression in human tumor cell lines. Blood 115: 4254-4263.
11. Swift S, Elliott S, Sinclair A, Begley CG, (2010) Erythropoietin Receptor in Ovarian Cancer Cells. Molecular Cancer Therapeutics 9: 1070-1071.
12. Keenan J, Dooley M, Pearson D, Clynes M, (1996) Recombinant human albumin in cell culture: evaluation of growth-promoting potential for NRK and SCC-9 cells in vitro. Cytotechnology 24: 252.
13. Slaaby R, Andersen AS, Brandt J, (2008) IGF-I binding to the IGF-I receptor is affected by contaminants in commercial BSA: the contaminants are proteins with IGF-I binding properties. Growth Hormone & Igf Research 18: 267-274.
14. Etherton TD, Chung CS, Wiggins JP, (1984) Receptor-dependent and independent degradation of insulin by isolated swine adipocytes at 37 C. Journal of Animal Science. 59: 366-375.
15. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, et al. (2011) LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1 integrin-mediated cell adhesion and liver metastasis. Cancer Research 71: 1989-1998.
16. Doan HQ, Bowen KA, Jackson LA, Evers BM, (2009) Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Research 29: 2473-2478.
17. Datta SR, Brunet A, Greenberg ME, (1999) Cellular survival: a play in three Akts. Genes & Development 13: 2905-2927.
18. Ammarguellat F, Llovera M, Kelly PA, Goffin V, (2001) Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochemical & Biophysical Research Communications 284: 1031-1038.
19. Lester RD, Jo M, Campana WM, Gonias SL, (2005) Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. Journal of Biological Chemistry 280: 39273-39277.
20. Gewirtz DA, Di X, Walker TD, Sawyer ST, (2006) Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs. Clinical Cancer Research 12: t-8.
21. Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, et al. (2006) Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Molecular Cancer Therapeutics 5: 356-361.
22. Dunlop EA, Percy MJ, Boland MP, Maxwell AP, Lappin TR, (2006) Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Neurodegenerative Diseases 3: 94-100.
23. Elliott S, Busse L, McCaffery I, Rossi J, Sinclair A, et al. (2010) Identification of a Sensitive Anti-Erythropoietin Receptor Monoclonal Antibody Allows Detection of Low Levels of EpoR in Cells. J Immunol Methods 352: 126-139.
24. Elliott S, Busse L, Swift S, McCaffery I, Rossi J, et al. (2012) Lack of expression and function of erythropoietin receptors in the kidney. Nephrology Dialysis Transplantation 27: 2733-2745.
25. Sinclair AM, Coxon A, McCaffery I, Kaufman S, Paweletz K, et al. (2010) Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 115: 4264-4272.
26. Komatsu N, Yamamoto M, Fujita H, Miwa A, Hatake K, et al. (1993) Establishment and characterization of an erythropoietin-dependent subline, UT-7/Epo, derived from human leukemia cell line, UT-7. Blood 82: 456-464.
27. Broudy VC, Lin N, Egrie J, de Haen C, Weiss T, et al. (1988) Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proceedings of the National Academy of Sciences of the United States of America 85: 6513-6517.
28. Papayannopoulou T, Nakamoto B, Kurachi S, Tweeddale M, Messner H, (1988) Surface antigenic profile and globin phenotype of two new human erythroleukemia lines: characterization and interpretations. Blood 72: 1029-1038.
29. Divoky V, Liu Z, Ryan TM, Prchal JF, Townes TM, et al. (2001) Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proceedings of the National Academy of Sciences of the United States of America 98: 986-991.
30. Hardee ME, Kirkpatrick JP, Shan S, Snyder SA, Vujaskovic Z, et al. (2005) Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. British Journal of Cancer 93: 1350-1355.
31. Yin D, Kawabata H, Tcherniamtchouk O, Huynh T, Black KL, et al. (2007) Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin. International Journal of Oncology 31: 1193-1198.
32. Fu P, Jiang X, Arcasoy MO, (2009) Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochemical & Biophysical Research Communications 379: 696-701.
33. Wenker SD, Chamorro ME, Vota DM, Callero MA, Vittori DC, et al. (2010) Differential antiapoptotic effect of erythropoietin on undifferentiated and retinoic acid-differentiated SH-SY5Y cells. Journal of Cellular Biochemistry 110: 151-161.
34. Zhang C, Duan XN, Xu L, Ye JM, Zhao JX, et al. (2012) Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Breast Cancer Research & Treatment 136: 739-748.
35. Neumann D, Wikstrom L, Watowich SS, Lodish HF, (1993) Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. Journal of Biological Chemistry 268: 13639-13649.
36. Hilton DJ, Watowich SS, Murray PJ, Lodish HF, (1995) Increased cell surface expression and enhanced folding in the endoplasmic reticulum of a mutant erythropoietin receptor. Proceedings of the National Academy of Sciences of the United States of America 92: 190-194.
37. Ebong S, Yu CR, Carper DA, Chepelinsky AB, Egwuagu CE, (2004) Activation of STAT signaling pathways and induction of suppressors of cytokine signaling (SOCS) proteins in mammalian lens by growth factors. Investigative Ophthalmology & Visual Science 45: 872-878.
38. Yuan ZL, Guan YJ, Wang L, Wei W, Kane AB, et al. (2004) Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells. Molecular & Cellular Biology 24: 9390-9400.
39. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ, (2008) Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. International Journal of Cancer 122: 274-280.
40. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, et al. (2006) Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Molecular Cancer Therapeutics 5: 347-355.
41. Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, et al. (2007) Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 25: 718-722.
42. Della Ragione F, Cucciolla V, Borriello A, Oliva A, Perrotta S, (2007) Erythropoietin receptors on cancer cells: a still open question. Journal of Clinical Oncology 25: 1812-1813.
43. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D, (2005) Correction of anaemia through the use of darbepoetin alfa improves chemotherapeutic outcome in a murine model of Lewis lung carcinoma. British Journal of Cancer 93: 224-232.
44. Bosman FT, (1988) Monoclonal antibodies in immunocytochemistry. Acta Histochemica- Supplementband 35: 27-32.
45. Lorincz A, Nusser Z, (2008) Specificity of immunoreactions: the importance of testing specificity in each method. Journal of Neuroscience 28: 9083-9086.
46. Leong AS, (2004) Pitfalls in diagnostic immunohistology. Advances in Anatomic Pathology 11: 86-93.
47. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, et al. (2010) Antibody validation. Biotechniques 48: 197-209.
48. Saper CB, (2009) A guide to the perplexed on the specificity of antibodies. Journal of Histochemistry & Cytochemistry 57: 1-5.
49. Fritschy JM, (2008) Is my antibody-staining specific? How to deal with pitfalls of immunohistochemistry. European Journal of Neuroscience 28: 2365-2370.
50. Hsi ED, (2001) A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Archives of Pathology & Laboratory Medicine 125: 289-294.
51. Inthal A, Krapf G, Beck D, Joas R, Kauer MO, et al. (2008) Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia. Clinical Cancer Research 14: 7196-7204.
52. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, et al. (2008) Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia (New York) 10: 932-939.
53. Sasaki Y, Kjellen E, Mineta H, Wennerberg J, Ekblad L, (2009) No direct effects of erythropoietin beta on a head and neck squamous cell carcinoma cell line which is growth stimulated in vivo. Acta Oncologica 48: 1062-1069.
54. Binder C, Lafayette A, Archibeque I, Sun Y, Plewa C, et al. (2008) Optimization and utilization of the SureFire phospho-STAT5 assay for a cell-based screening campaign. Assay & Drug Development Technologies 6: 27-37.
55. Migliaccio AR, Migliaccio G, D'Andrea A, Baiocchi M, Crotta S, et al. (1991) Response to erythropoietin in erythroid subclones of the factor-dependent cell line 32D is determined by translocation of the erythropoietin receptor to the cell surface. Proceedings of the National Academy of Sciences of the United States of America 88: 11086-11090.
56. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T, (1991) Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77: 2583-2590.
57. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC, (1992) Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80: 1940-1949.
58. McArthur GA, Longmore GD, Klingler K, Johnson GR, (1995) Lineage-restricted recruitment of immature hematopoietic progenitor cells in response to Epo after normal hematopoietic cell transfection with EpoR. Experimental Hematology 23: 645-654.
59. Santucci MA, Pierce JH, Zannini S, Fortuna A, Frezza G, et al. (1994) Erythropoietin increases the radioresistance of a clonal hematopoietic progenitor cell line expressing a transgene for the erythropoietin receptor. Stem Cells 12: 506-513.
60. Yawata H, Yasukawa K, Natsuka S, Murakami M, Yamasaki K, et al. (1993) Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO Journal 12: 1705-1712.
61. Kessler C, Greindl A, Breuer B, Haberl U, Rybka A, et al. (2012) Erythropoietin mimetic compound AGEM400(HES) binds to the same receptor as erythropoietin but displays a different spectrum of activities. Cytokine 57: 226-237.
62. Jegalian AG, Acurio A, Dranoff G, Wu H, (2002) Erythropoietin receptor haploinsufficiency and in vivo interplay with granulocyte-macrophage colony-stimulating factor and interleukin 3. Blood 99: 2603-2605.
63. Broudy VC, Nakamoto B, Lin N, Papayannopoulou T, (1990) Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines. Blood 75: 1622-1626.
64. Wognum AW, Lansdorp PM, Humphries RK, Krystal G, (1990) Detection and isolation of the erythropoietin receptor using biotinylated erythropoietin. Blood 76: 697-705.
65. Wognum AW, Krystal G, Eaves CJ, Eaves AC, Lansdorp PM, (1992) Increased erythropoietin-receptor expression on CD34-positive bone marrow cells from patients with chronic myeloid leukemia. Blood 79: 642-649.
66. Fraser JK, Lin FK, Berridge MV, (1988) Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Experimental Hematology 16: 836-842.
67. Mitjavila MT, Natazawa M, Brignaschi P, Debili N, Breton-Gorius J, et al. (1989) Effects of five recombinant hematopoietic growth factors on enriched human erythroid progenitors in serum-replaced cultures. Journal of Cellular Physiology 138: 617-623.
68. Gaffen SL, Lai SY, Longmore GD, Liu KD, Goldsmith MA, (1999) Genetic evidence for an additional factor required for erythropoietin-induced signal transduction. Blood 94: 74-86.
69. D'Andrea AD, Jones SS, (1991) Activation of the erythropoietin receptor in stable lymphoid and myeloid transfectants. Seminars in Hematology 28: 152-157.
70. Shikama Y, Barber DL, D'Andrea AD, Sieff CA, (1996) A constitutively activated chimeric cytokine receptor confers factor-independent growth in hematopoietic cell lines. Blood 88: 455-464.
71. Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A, (1995) Interleukin 2 and erythropoietin activate STAT5/MGF via distinct pathways. EMBO Journal 14: 2527-2535.
72. Yamamura Y, Kageyama Y, Matuzaki T, Noda M, Ikawa Y, (1992) Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor. EMBO Journal 11: 4909-4915.
73. Minamoto S, Treisman J, Hankins WD, Sugamura K, Rosenberg SA, (1995) Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors. Blood 86: 2281-2287.
74. Longmore GD, Lodish HF, (1991) An activating mutation in the murine erythropoietin receptor induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell 67: 1089-1102.
75. Kang JK, Chang CH, Nam HJ, Kim SK, Ahn KJ, et al. (2011) Downregulation of erythropoietin receptor by overexpression of phospholipase C-gamma 1 is critical for decrease on focal adhesion in transformed cells. Cellular Oncology 34: 11-21.
76. Layon ME, Ackley CJ, West RJ, Lowrey CH, (2007) Expression of GATA-1 in a non-hematopoietic cell line induces beta-globin locus control region chromatin structure remodeling and an erythroid pattern of gene expression. Journal of Molecular Biology 366: 737-744.
77. Miura Y, Miura O, Ihle JN, Aoki N, (1994) Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. Journal of Biological Chemistry 269: 29962-29969.
78. Zou X, Calame K, (1999) Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. Journal of Biological Chemistry 274: 18141-18144.